Pharmaceuticals, Corporate Crime and Public Health

Pharmaceuticals, Corporate Crime and Public Health

Graham Dukes, John Braithwaite and J. P. Moloney

The pharmaceutical industry exists to serve the community, but over the years it has engaged massively in corporate crime, with the public footing the bill. This readable study by experts in medicine, law, criminology and public health documents the problems, ranging from false advertising and counterfeiting to corruption waste and overpricing, with unacceptable pressures on doctors, politicians, patients and the media. Uniquely, the book goes on to present a realistic and worldwide solution for the future, with positive policies encouraging honest dealing as well as partial privatization of enforcement and greater emphasis on creative research to develop the medicines that society needs most.

Chapter 4: The dark art of manipulation: The industry and its puppets

Graham Dukes, John Braithwaite and J. P. Moloney

Subjects: law - academic, biotechnology and pharmaceutical law, health law, social policy and sociology, health policy and economics

Extract

The verb “to manipulate” is used in several senses of which dictionaries duly take note. It is derived from the Latin term manipulus, meaning a handful; the body or object to be manipulated is in other words directly taken in hand in order to influence it. The process may be entirely open and necessary; the engineer, for example, is supposed to manipulate the controls of a machine in order to cause it to operate in an appropriate manner. However, there is also such a thing as covert manipulation; the Concise Oxford Dictionary recognizes this meaning of the term: to manipulate in this sense is to “manage (a person, situation etc.) to one’s own advantage, especially unfairly or unscrupulously”. It is in the latter sense that we use the term in this chapter. In examining these matters one needs to appreciate that the processes of good governance and honest health care must be open to helpful influences from any quarter. To that end there are consultative committees, hearings and opportunities for lobbying by any relevant party, whether that party represents business, science, the professions or any other interest. The essential element in such provisions is openness; one must know that the lobbying is taking place, the parties involved, the content and the outcome.

You are not authenticated to view the full text of this chapter or article.

Elgaronline requires a subscription or purchase to access the full text of books or journals. Please login through your library system or with your personal username and password on the homepage.

Non-subscribers can freely search the site, view abstracts/ extracts and download selected front matter and introductory chapters for personal use.

Your library may not have purchased all subject areas. If you are authenticated and think you should have access to this title, please contact your librarian.

Further information